The Experience of Successful Use of Adalimumab in a Patient With Juvenile Arthritis Associated With Enthesitis and Uveitis
https://doi.org/10.15690/pf.v14i4.1761
Abstract
The article describes the case of successful use of human monoclonal antibodies to the tumor necrosis factor- adalimumab in a patient with a severe course of juvenile arthritis associated with enthesitis and uveitis resistant to non-steroidal anti-inflammatory drugs, methotrexate, glucocorticosteroids that have been applied topically and retrobulbarly. After the first adalimumab administration, the pain syndrome was stopped, the duration of morning stiffness was significantly reduced, the laboratory indices of the disease activity were normalized by the 4th week of treatment, uveitis activity was stopped, the inflammatory changes in the joints regressed and the phase of inactive disease was ascertained by the 12th week. The duration of remission of articular syndrome and uveitis during treatment with adalimumab was 26 months. Adverse reactions were not registered during therapy.
About the Authors
Aleksandra M. Chomakhidze
National Medical Research Center of Children’s Health
Russian Federation
Russian Federation
Ekaterina I. Alexeeva
National Medical Research Center of Children’s Health
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
Rina V. Denisova
National Medical Research Center of Children’s Health
Russian Federation
Russian Federation
References
1. Cassidy JT, Petty RE, Laxer RM, Lindsley CB. Textbook of pediatric rheumatology. 6th ed. Philadelphia: Saunders Company; 2001. pp. 218–322.
2. Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390–392.
3. Детская ревматология. Атлас / Под ред. Баранова А.А., Алексеевой Е.И. 2-е издание, переработ. и доп. — М.: ПедиатрЪ; 2015. — 384 с. [Detskaya revmatologiya. Atlas. Ed by Baranov A.A., Alexeeva E.I. 2nd ed, updated and revised. Moscow: Pediatr””; 2015. 384 p. (In Russ).]
4. Алексеева Е.И., Литвицкий П.Ф. Ювенильный ревматоидный артрит: этиология, патогенез, клиника, алгоритмы диагностики и лечения. Руководство для врачей, преподавателей, научных сотрудников / Под общей ред. Баранова А.А. — М.: ВЕДИ; 2007. — 368 с. [Alexeeva EI, Litvitskii PF. Yuvenil’nyi revmatoidnyi artrit: etiologiya, patogenez, klinika, algoritmy diagnostiki i lecheniya. Rukovodstvo dlya vrachei, prepodavatelei, nauchnykh sotrudnikov. Ed by Baranov A.A. Moscow: VEDI; 2007. 368 p. (In Russ).]
5. Rosenberg KD, Feuer WJ, Davis JL. Ocular complications of pediatric uveitis. Ophthalmology. 2004;111(12):2299–2306. doi: 10.1016/j.ophtha.2004.06.014.
6. Hashkes PJ, Laxer RM. Medical treatment of juvenile idiopathic arthritis. JAMA. 2005;294(13):1671–1684. doi: 10.1001/jama.294.13.1671.
7. Horneff G. Update on biologicals for treatment of juvenileidiopathic arthritis. Exp Opin Biol Ther. 2013;13(3):361–376. doi: 10.1517/14712598.2013.735657.
8. Катаргина Л.А., Архипова Л.Т. Увеиты: патогенетическая иммуносупрессивная терапия. — Тверь; 2004. — 99 с. [Katargina LA, Arkhipova LT. Uveity: patogeneticheskaya immunosupressivnaya terapiya. Tver; 2004. 99 p. (In Russ).]
9. Катаргина Л.А., Хватова А.В. Эндогенные увеиты у детей и подростков. — М.: Медицина; 2000. — 320 с. [Katargina LA, Khvatova AV. Endogennye uveity u detei i podrostkov. Moscow: Meditsina; 2000. 320 p. (In Russ).]
10. Stoll ML, Cron RQ. Treatment of juvenile idiopathic arthritis: a revolution in care. Pediatr Rheumatol Online J. 2014;12:13. doi: 10.1186/1546-0096-12-13.
11. Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359(8):810–820. doi: 10.1056/NEJMoa0706290.
12. Lovell DJ, Ruperto N, Reiff A, et al. Long-term efficacy and safety of adalimumab for up to 6 years in patients with juvenile idiopathic arthritis. Arthritis Rheum. 2011;63(Suppl 10):265.
13. Burgos-Vargas R, Tse SML, Horneff G, et al. Efficacy and safety of adalimumab in pediatric patients with enthesitis related arthritis. Arthritis Rheumatol. 2014;66(S3):S4. doi: 10.1002/art.38414.
14. Imagawa T, Takei S, Umebayashi H, et al. Efficacy, pharmaco ki netics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan. Clin Rheumatol. 2012;31(12): 1713–1721. doi: 10.1007/s10067-012-2082-5.
15. Biester S, Deuter C, Michels H, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol. 2007;91(3):319–324. doi: 10.1136/bjo.2006.103721.
16. Kotaniemi K, Saila H, Kautiainen H. Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis. Clin Ophthalmol. 2011;5:1425–1429. doi: 10.2147/OPTH.S23646.
Review
For citations:
Chomakhidze A.M., Alexeeva E.I., Denisova R.V. The Experience of Successful Use of Adalimumab in a Patient With Juvenile Arthritis Associated With Enthesitis and Uveitis. Pediatric pharmacology. 2017;14(4):294-299. (In Russ.) https://doi.org/10.15690/pf.v14i4.1761
Views:
642
Email this article 